The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters
[ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive
performance and global function in patients with probable Alzheimer's Disease (AD). It should
also be assessed if the treatments have a positive effect on activities of daily living and
Oral treatment with Aricept or Placebo was given once daily throughout the study. Intravenous
treatment with Cerebrolysin or Placebo was given once daily for 5 days per week during week 1
to 4 and during week 13 to 16 of the study. During the study patients had six visits at the
hospital for evaluation.